SEOUL, May 15 (Korea Bizwire) — Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday its business will remain largely unaffected by U.S. President Donald Trump’s executive order aimed at lowering drug prices to match those in other countries. The order seeks to address a drug pricing system in which the United States pays [...]
SEOUL, May 14 (Korea Bizwire) — South Korea’s pharmaceutical and biotech companies view the Trump administration’s push to lower U.S. prescription drug prices as a potential tailwind for domestic drugmakers, particularly those in the biosimilar space. Former President Donald Trump, who is expected to run again in the 2026 election, issued an executive order last week [...]
SEOUL, May 7 (Korea Bizwire) — The Korea Biotechnology Industry Organization (KBIO) said Wednesday it has requested the United States to exempt South Korea from the Donald Trump administration’s plan to impose tariffs on pharmaceutical imports. KBIO said it submitted such an opinion formally to the U.S. Department of Commerce on Tuesday (U.S. time) regarding [...]
SEOUL, May 6 (Korea Bizwire) — South Korea’s retail sector is undergoing a transformation, with department stores, convenience chains, e-commerce platforms, and home shopping networks all doubling down on health supplements as a key growth driver in the post-pandemic era. Spurred by the rise of the “Healthy Pleasure” lifestyle — where consumers actively enjoy health management [...]
SEOUL, May 5 (Korea Bizwire) — As global competition heats up in the pharmaceutical and biotech sectors, major players in South Korea and abroad are accelerating efforts to expand the therapeutic indications of existing drugs—a strategy aimed at maximizing product value and securing wider market share. According to industry sources on May 4, Korea Novo Nordisk [...]
SEOUL, April 25, (Korea Bizwire) — South Korea’s biohealth industry is projected to grow at an annual rate of nearly 9 percent, reaching $370.3 billion by 2030 and ranking eighth globally, according to a new market outlook released by the Korea Health Industry Development Institute (KHIDI) on April 25. The report, titled 2025 Global Biohealth [...]
SEOUL, April 23 (Korea Bizwire) – SK bioscience Co., the biopharmaceutical arm of South Korea’s SK Group, said Wednesday it has achieved a “final victory” in a patent invalidation case against Moderna, the global developer of the messenger-RNA (mRNA) COVID-19 vaccine. SK bioscience filed a nullity suit in 2023 challenging Moderna’s patent on modified nucleosides, [...]
SEOUL, April 23 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Wednesday its first-quarter net profit more than doubled from a year earlier, driven by expanded production and a weaker won. Net profit for the three months ended March surged to 375.6 billion won (US$263.9 million), up from [...]
SEOUL, April 22, (Korea Bizwire) — Intensifying competition from biosimilars and the looming expiration of lucrative drug patents have emerged as the foremost concerns for global pharmaceutical, biotech, and medical device companies, according to a 2025 report by Deloitte Korea. The report, titled “Five Key Challenges for the Global Pharmaceutical and Biotech Industry in 2025,” [...]
SEOUL, April 14 (Korea Bizwire) — Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday it has obtained an interchangeability approval for its biosimilar drug for autoimmune disease treatment in the United States. The U.S. Food and Drug Administration (FDA) designated Celltrion’s biosimilar Yuflyma as interchangeable medicine for its original drug Humira in the [...]